PPCH Company Description
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc, together with its scientific and oncology consultants, has developed a rational, composite formulation of anti-cancer compounds which together exert a number of anti-cancer actions. Propanc's leading products are novel, patented formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects, Propanc intends to progress their lead product along the rigorous, formal non-clinical and clinical development pathway required to obtain regulatory approval to market its proenzyme formulation. Propanc intends to undertake development of manufacturing, formal non-clinical studies and then Phase I, II and III clinical trials in order to generate the quality, safety and efficacy data required for regulatory approval. For more information, please visit: http://www.propanc.com




PPCH Products and Services
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc was established in 2007 and located in Melbourne, Australia.

Highlights
Targeted therapy for metastatic cancer: Global demand for effective, safe and easy to administer cancer treatments increasing rapidly.

Expansive market demand: Seeking worldwide regulatory approval in several indications, targeting tumor types where few treatment options exist.

Multiple mechanisms of action: Our lead product exerts multiple effects inhibiting tumor growth & blood supply, and stopping it spreading. R&D may identify opportunities for developing new compounds.

Encouraging patient data: 15 years of scientific research and clinical experience suggests our lead product may be an effective treatment against cancer and warrants further development.

Unique intellectual property: Propanc is building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, new formulations, new routes of
administration and potential new targets